. 2016 Jan 11;2(1):e000137. doi: 10.1136/rmdopen-2015-000137
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Figure 1.
Positron emission tomography-computerised tomography pretocilizumab (TCZ) (A) and post six cycles TCZ (B).